• Arch. Pathol. Lab. Med. · Jun 2019

    Analytical Validation and Clinical Utility of an Immunohistochemical Programmed Death Ligand-1 Diagnostic Assay and Combined Tumor and Immune Cell Scoring Algorithm for Durvalumab in Urothelial Carcinoma.

    • Magdalena Zajac, Anne-Marie Boothman, Yong Ben, Ashok Gupta, Xiaoping Jin, Amita Mistry, Constantine Sabalos, Alma Nielsen, Guadalupe Manriquez, Craig Barker, Joyce Antal, Peiyi Wang, Pallavi Patil, Nicole Schechter, Marlon C Rebelatto, and Jill Walker.
    • From Precision Medicine and Genomics, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom (Drs Zajac, Boothman, and Walker and Mr Barker); Global Medicines Development, AstraZeneca, Gaithersburg, Maryland (Dr Ben); Clinical Development (Dr Gupta and Ms Antal), Biostatistics (Dr Jin), and Translational Sciences and Pathology (Dr Rebelatto), MedImmune, Gaithersburg, Maryland; and Roche Tissue Diagnostics, Ventana Medical Systems Inc, Tucson, Arizona (Drs Mistry, Manriquez, and Patil, Mr Sabalos, and Mss Nielsen, Wang, and Schechter). Dr Ben is currently affiliated with BioAtla, San Diego, California. Dr Jin is currently affiliated with Akeso Biopharma Inc, Zhongshan, Guangdong, China. Ms Antal is currently affiliated with G1 Therapeutics Inc, Research Triangle Park, North Carolina.
    • Arch. Pathol. Lab. Med. 2019 Jun 1; 143 (6): 722-731.

    Context.—Clinical responses to anti-programmed death receptor-1 and anti-programmed death ligand-1 (PD-L1) agents are generally improved in patients with high PD-L1 expression compared with those with low/negative expression across several tumor types, including urothelial carcinoma.Objective.—To validate a PD-L1 immunohistochemical diagnostic test in urothelial carcinoma patients treated with the anti-PD-L1 monoclonal antibody durvalumab.Design.—The Ventana PD-L1 (SP263) assay was validated for intended use in urothelial carcinoma formalin-fixed, paraffin-embedded samples in studies addressing sensitivity, specificity, robustness, and precision, and implemented in study CD-ON-MEDI4736-1108 (NCT01693562). Efficacy was analyzed in patients classified according to prespecified PD-L1 expression cutoffs: PD-L1 high (if >1% of the tumor area contained tumor-associated immune cells, ≥25% of tumor cells or ≥25% of immune cells stained for PD-L1; if ≤1% of the tumor area contained immune cells, ≥25% of tumor cells or 100% of immune cells stained for PD-L1) and PD-L1 low/negative (did not meet criteria for PD-L1 high).Results.—The assay met all predefined acceptance criteria for sensitivity, specificity, and precision. Interreader and intrareader precision overall agreement were 93.0% and 92.4%, respectively. For intraday reproducibility and interday precision, overall agreement was 99.2% and 100%, respectively. Interlaboratory overall agreement was 92.6%. In study CD-ON-MEDI4736-1108, durvalumab demonstrated clinical activity and durable responses in both PD-L1-high and PD-L1-low/negative subgroups, although objective response rates tended to be higher in the PD-L1-high subgroup than in the PD-L1-low/negative subgroup.Conclusions.—Determination of PD-L1 expression in urothelial carcinoma patients using the Ventana PD-L1 (SP263) assay was precise, highly reproducible, and clinically relevant.

      Pubmed     Free full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…

What will the 'Medical Journal of You' look like?

Start your free 21 day trial now.

We guarantee your privacy. Your email address will not be shared.